Cargando…

AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software

Objective: To develop a novel software method (AR2) for reducing muscle contamination of ictal scalp electroencephalogram (EEG), and validate this method on the basis of its performance in comparison to a commercially available software method (AR1) to accurately depict seizure-onset location. Metho...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiss, Shennan Aibel, Asadi-Pooya, Ali A, Vangala, Sitaram, Moy, Stephanie, Wyeth, Dale H, Orosz, Iren, Gibbs, Michael, Schrader, Lara, Lerner, Jason, Cheng, Christopher K, Chang, Edward, Rajaraman, Rajsekar, Keselman, Inna, Churchman, Perdro, Bower-Baca, Christine, Numis, Adam L, Ho, Michael G, Rao, Lekha, Bhat, Annapoorna, Suski, Joanna, Asadollahi, Marjan, Ambrose, Timothy, Fernandez, Andres, Nei, Maromi, Skidmore, Christopher, Mintzer, Scott, Eliashiv, Dawn S, Mathern, Gary W, Nuwer, Marc R, Sperling, Michael, Engel Jr, Jerome, Stern, John M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399961/
https://www.ncbi.nlm.nih.gov/pubmed/28491280
http://dx.doi.org/10.12688/f1000research.10569.2
_version_ 1783230738612617216
author Weiss, Shennan Aibel
Asadi-Pooya, Ali A
Vangala, Sitaram
Moy, Stephanie
Wyeth, Dale H
Orosz, Iren
Gibbs, Michael
Schrader, Lara
Lerner, Jason
Cheng, Christopher K
Chang, Edward
Rajaraman, Rajsekar
Keselman, Inna
Churchman, Perdro
Bower-Baca, Christine
Numis, Adam L
Ho, Michael G
Rao, Lekha
Bhat, Annapoorna
Suski, Joanna
Asadollahi, Marjan
Ambrose, Timothy
Fernandez, Andres
Nei, Maromi
Skidmore, Christopher
Mintzer, Scott
Eliashiv, Dawn S
Mathern, Gary W
Nuwer, Marc R
Sperling, Michael
Engel Jr, Jerome
Stern, John M
author_facet Weiss, Shennan Aibel
Asadi-Pooya, Ali A
Vangala, Sitaram
Moy, Stephanie
Wyeth, Dale H
Orosz, Iren
Gibbs, Michael
Schrader, Lara
Lerner, Jason
Cheng, Christopher K
Chang, Edward
Rajaraman, Rajsekar
Keselman, Inna
Churchman, Perdro
Bower-Baca, Christine
Numis, Adam L
Ho, Michael G
Rao, Lekha
Bhat, Annapoorna
Suski, Joanna
Asadollahi, Marjan
Ambrose, Timothy
Fernandez, Andres
Nei, Maromi
Skidmore, Christopher
Mintzer, Scott
Eliashiv, Dawn S
Mathern, Gary W
Nuwer, Marc R
Sperling, Michael
Engel Jr, Jerome
Stern, John M
author_sort Weiss, Shennan Aibel
collection PubMed
description Objective: To develop a novel software method (AR2) for reducing muscle contamination of ictal scalp electroencephalogram (EEG), and validate this method on the basis of its performance in comparison to a commercially available software method (AR1) to accurately depict seizure-onset location. Methods: A blinded investigation used 23 EEG recordings of seizures from 8 patients. Each recording was uninterpretable with digital filtering because of muscle artifact and processed using AR1 and AR2 and reviewed by 26 EEG specialists. EEG readers assessed seizure-onset time, lateralization, and region, and specified confidence for each determination. The two methods were validated on the basis of the number of readers able to render assignments, confidence, the intra-class correlation (ICC), and agreement with other clinical findings. Results: Among the 23 seizures, two-thirds of the readers were able to delineate seizure-onset time in 10 of 23 using AR1, and 15 of 23 using AR2 (p<0.01). Fewer readers could lateralize seizure-onset (p<0.05). The confidence measures of the assignments were low (probable-unlikely), but increased using AR2 (p<0.05). The ICC for identifying the time of seizure-onset was 0.15 (95% confidence interval (CI), 0.11-0.18) using AR1 and 0.26 (95% CI 0.21-0.30) using AR2.  The EEG interpretations were often consistent with behavioral, neurophysiological, and neuro-radiological findings, with left sided assignments correct in 95.9% (CI 85.7-98.9%, n=4) of cases using AR2, and 91.9% (77.0-97.5%) (n=4) of cases using AR1. Conclusions: EEG artifact reduction methods for localizing seizure-onset does not result in high rates of interpretability, reader confidence, and inter-reader agreement. However, the assignments by groups of readers are often congruent with other clinical data. Utilization of the AR2 software method may improve the validity of ictal EEG artifact reduction.
format Online
Article
Text
id pubmed-5399961
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-53999612017-05-09 AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software Weiss, Shennan Aibel Asadi-Pooya, Ali A Vangala, Sitaram Moy, Stephanie Wyeth, Dale H Orosz, Iren Gibbs, Michael Schrader, Lara Lerner, Jason Cheng, Christopher K Chang, Edward Rajaraman, Rajsekar Keselman, Inna Churchman, Perdro Bower-Baca, Christine Numis, Adam L Ho, Michael G Rao, Lekha Bhat, Annapoorna Suski, Joanna Asadollahi, Marjan Ambrose, Timothy Fernandez, Andres Nei, Maromi Skidmore, Christopher Mintzer, Scott Eliashiv, Dawn S Mathern, Gary W Nuwer, Marc R Sperling, Michael Engel Jr, Jerome Stern, John M F1000Res Software Tool Article Objective: To develop a novel software method (AR2) for reducing muscle contamination of ictal scalp electroencephalogram (EEG), and validate this method on the basis of its performance in comparison to a commercially available software method (AR1) to accurately depict seizure-onset location. Methods: A blinded investigation used 23 EEG recordings of seizures from 8 patients. Each recording was uninterpretable with digital filtering because of muscle artifact and processed using AR1 and AR2 and reviewed by 26 EEG specialists. EEG readers assessed seizure-onset time, lateralization, and region, and specified confidence for each determination. The two methods were validated on the basis of the number of readers able to render assignments, confidence, the intra-class correlation (ICC), and agreement with other clinical findings. Results: Among the 23 seizures, two-thirds of the readers were able to delineate seizure-onset time in 10 of 23 using AR1, and 15 of 23 using AR2 (p<0.01). Fewer readers could lateralize seizure-onset (p<0.05). The confidence measures of the assignments were low (probable-unlikely), but increased using AR2 (p<0.05). The ICC for identifying the time of seizure-onset was 0.15 (95% confidence interval (CI), 0.11-0.18) using AR1 and 0.26 (95% CI 0.21-0.30) using AR2.  The EEG interpretations were often consistent with behavioral, neurophysiological, and neuro-radiological findings, with left sided assignments correct in 95.9% (CI 85.7-98.9%, n=4) of cases using AR2, and 91.9% (77.0-97.5%) (n=4) of cases using AR1. Conclusions: EEG artifact reduction methods for localizing seizure-onset does not result in high rates of interpretability, reader confidence, and inter-reader agreement. However, the assignments by groups of readers are often congruent with other clinical data. Utilization of the AR2 software method may improve the validity of ictal EEG artifact reduction. F1000Research 2017-04-04 /pmc/articles/PMC5399961/ /pubmed/28491280 http://dx.doi.org/10.12688/f1000research.10569.2 Text en Copyright: © 2017 Weiss SA et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Software Tool Article
Weiss, Shennan Aibel
Asadi-Pooya, Ali A
Vangala, Sitaram
Moy, Stephanie
Wyeth, Dale H
Orosz, Iren
Gibbs, Michael
Schrader, Lara
Lerner, Jason
Cheng, Christopher K
Chang, Edward
Rajaraman, Rajsekar
Keselman, Inna
Churchman, Perdro
Bower-Baca, Christine
Numis, Adam L
Ho, Michael G
Rao, Lekha
Bhat, Annapoorna
Suski, Joanna
Asadollahi, Marjan
Ambrose, Timothy
Fernandez, Andres
Nei, Maromi
Skidmore, Christopher
Mintzer, Scott
Eliashiv, Dawn S
Mathern, Gary W
Nuwer, Marc R
Sperling, Michael
Engel Jr, Jerome
Stern, John M
AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software
title AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software
title_full AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software
title_fullStr AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software
title_full_unstemmed AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software
title_short AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software
title_sort ar2, a novel automatic muscle artifact reduction software method for ictal eeg interpretation: validation and comparison of performance with commercially available software
topic Software Tool Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399961/
https://www.ncbi.nlm.nih.gov/pubmed/28491280
http://dx.doi.org/10.12688/f1000research.10569.2
work_keys_str_mv AT weissshennanaibel ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT asadipooyaalia ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT vangalasitaram ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT moystephanie ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT wyethdaleh ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT orosziren ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT gibbsmichael ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT schraderlara ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT lernerjason ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT chengchristopherk ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT changedward ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT rajaramanrajsekar ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT keselmaninna ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT churchmanperdro ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT bowerbacachristine ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT numisadaml ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT homichaelg ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT raolekha ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT bhatannapoorna ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT suskijoanna ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT asadollahimarjan ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT ambrosetimothy ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT fernandezandres ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT neimaromi ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT skidmorechristopher ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT mintzerscott ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT eliashivdawns ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT matherngaryw ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT nuwermarcr ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT sperlingmichael ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT engeljrjerome ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware
AT sternjohnm ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware